CMRX up +4.09% percent Today $CMRX High is at 34.20 and the Low 32.25 with current volume of 131,406.
Recent News posted below.
Chimerix Inc CMRX other info.
http://investorshangout.com/Chimerix-Inc-CMRX-90543/
CMRX Chimerix Inc Recent Headline News
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 22.85 (+0.24), JNJ: 108.27 (+0.11), BCRX: 10.04 (-0.03), NAVB: 1.24 (+0.08), CMRX: 33.52 (+1.28), SRPT: 15.20 (-0.12), NBS: 6.90 (+0.73), TKMR: 17.26 (+0.85), GSK: 45.84 (+0.10), CEMP: 13.85 (+0.25), OMER: 19.51 (+0.53)
Chimerix's Brincidofovir Selected for Use in Ebola Clinical Trial in West Africa by International Consortium
GlobeNewswire - Thu Nov 13, 11:30AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that its investigational broad-spectrum antiviral brincidofovir has been selected as one of two investigational agents to be evaluated in a clinical study in patients with confirmed Ebola Virus Disease in west Africa. Chimerix and the University of Oxford are in the process of finalizing a definitive agreement for supplying brincidofovir for the planned clinical trial.
CMRX: 33.52 (+1.28)
Global Ebola Viral Infections Clinical Trials Report H2, 2014 - Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/wtw3b6/ebola_viral) has announced the addition of the "Ebola Viral Infections Global Clinical Trials Review, H2, 2014" report to their offering. Ebola Viral Infections Global Clinical Trials Review, H2, 2014" provides data on the Ebola Viral Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ebola Viral Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ebola Viral Infections. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Tekmira Pharmaceuticals Corp. - Sarepta Therapeutics, Inc. - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Chimerix, Inc. Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Academy of Military Medical Sciences - University of Oxford For more information visit http://www.researchandmarkets.com/research/wt...bola_viral
INO: 10.18 (-0.82), CMRX: 33.52 (+1.28), SRPT: 15.20 (-0.12), TKMR: 17.26 (+0.85), GSK: 45.84 (+0.10)
Chimerix to Present at the Stifel Healthcare Conference
GlobeNewswire - Tue Nov 11, 7:01AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 3:35pm EST at The New York Palace Hotel in New York.
CMRX: 33.52 (+1.28)
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 35.70 (+0.48), CMRX: 33.52 (+1.28), CVM: 0.63 (-0.02), ADMP: 4.01 (-0.08), GNCA: 8.99 (+0.09)
InsiderInsights.com Daily Round Up 11/6/14: Chimerix, Biolase, Barrett Business Services, Ares Capital
InsiderInsights - at Seeking Alpha - Fri Nov 07, 1:06PM CST
72.01 (+0.44), CBG: 32.39 (-0.01), PBFX: 24.20 (+0.52), LLY: 67.22 (-0.11), RL: 175.58 (+1.34), GOOG: 535.61 (-8.79), AER: 43.13 (-0.42), DO: 35.41 (-0.40), TPVG: 14.62 (+0.06), ARCC: 16.26 (-0.12), CMRX: 33.52 (+1.28), OPK: 8.24 (-0.05), BIOL: 2.37 (+0.02), WRI: 35.93 (+0.33), BBSI: 22.36 (-0.24), CUDA: 35.21 (-0.13), ACGL: 56.90 (-0.40), KPTI: 40.19 (+0.42)
Chimerix's (CMRX) CEO Michelle Berrey on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 12:33PM CST
CMRX: 33.52 (+1.28)
Chimerix misses by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:19AM CST
CMRX: 33.52 (+1.28)
Chimerix Announces Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial results and a corporate update for the third quarter 2014.
CMRX: 33.52 (+1.28)
Chimerix Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock
GlobeNewswire - Wed Nov 05, 3:38PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the completion of an underwritten public offering of 4,197,500 shares of its common stock, including 547,500 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Chimerix at a price to the public of $29 per share. The gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, were approximately $121.7 million. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
CMRX: 33.52 (+1.28), MS: 35.65 (-0.04)
Chimerix Names Two New Executives: Peter Payne as Senior Vice President, Business Development and Corporate Strategy, and Roberto Guzman, JD, MBA, MCLFS, as Vice President, Corporate Compliance
GlobeNewswire - Mon Nov 03, 5:31PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals, today announced the appointments of Peter Payne as Senior Vice President of Business Development and Corporate Strategy, and Roberto Guzman as Vice President of Corporate Compliance. Mr. Payne will oversee Chimerix's Business Development efforts as the company continues to derive additional value from its pipeline and evaluate complementary products that may further enhance the company's portfolio. Mr. Guzman will have responsibility for the design, implementation, and oversight of the Chimerix Compliance Program.
CMRX: 33.52 (+1.28)
Chimerix to Announce Third Quarter Financial Results on November 7, 2014
GlobeNewswire - Fri Oct 31, 4:58PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it will report financial results for the third quarter ended September 30, 2014, on Friday, November 7, 2014, before the market opens. Chimerix's management team will host a live conference call and audio webcast at 8:30 a.m. ET on Friday, November 7, 2014 to discuss the Company's results and to provide a business overview.
CMRX: 33.52 (+1.28)
Chimerix Prices Public Offering of Common Stock
GlobeNewswire - Thu Oct 30, 5:37PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the pricing of an underwritten public offering of 3,650,000 shares of its common stock at a price to the public of $29 per share. The gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, are expected to be approximately $105.9 million. The offering is expected to close on or about November 5, 2014, subject to customary closing conditions. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
CMRX: 33.52 (+1.28), MS: 35.65 (-0.04)
Chimerix Announces Commencement of Public Offering of Common Stock
GlobeNewswire - Wed Oct 29, 4:30PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it intends to offer and sell, subject to market and other conditions, approximately $105,000,000 of its common stock in an underwritten public offering. In connection with this offering, Chimerix expects to grant the underwriters a 30-day option to purchase up to approximately $15,750,000 of additional shares of its common stock. Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering, and Cowen and Company, LLC, Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as co-lead managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
CMRX: 33.52 (+1.28), JPM: 60.34 (+0.06), MS: 35.65 (-0.04)
CDC issues new guidelines over Ebola
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:10AM CDT
BCRX: 10.04 (-0.03), VSR: 2.96 (-0.03), TKMR: 17.26 (+0.85), NNVC: 3.24 (-0.15), INO: 10.18 (-0.82), CMRX: 33.52 (+1.28), APT: 2.93 (+0.01), HEB: 0.28 (+0.01), SRPT: 15.20 (-0.12), SMED: 4.33 (-0.05), NLNK: 31.00 (+0.46), PLX: 2.13 (+0.04), LAKE: 11.40 (+0.34), NSPH: 0.44 (unch)
Ebola Hits NYC: Time To Panic
Matthew Finston - at Seeking Alpha - Mon Oct 27, 7:45AM CDT
BCRX: 10.03 (-0.04), TKMR: 17.26 (+0.85), NNVC: 3.24 (-0.15), INO: 10.18 (-0.82), CMRX: 33.52 (+1.28), APT: 2.93 (+0.01), HEB: 0.28 (+0.01), SRPT: 15.19 (-0.13), NLNK: 31.00 (+0.46), PLX: 2.13 (+0.04), SMED: 4.33 (-0.05), LAKE: 11.40 (+0.34), NSPH: 0.44 (unch), OSUR: 8.80 (+0.03)
Mali confirms first Ebola case
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 3:48AM CDT
BCRX: 10.03 (-0.04), GOLD: 67.74 (-1.01), AU: 9.26 (-0.30), VSR: 2.96 (-0.03), TKMR: 17.26 (+0.85), NNVC: 3.24 (-0.15), INO: 10.18 (-0.82), CMRX: 33.52 (+1.28), APT: 2.93 (+0.01), HEB: 0.28 (+0.01), SRPT: 15.19 (-0.13), SMED: 4.33 (-0.05), NLNK: 31.00 (+0.46), PLX: 2.13 (+0.04), LAKE: 11.40 (+0.34), NSPH: 0.44 (unch)
NYC doctor tests positive for Ebola; futures slip
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 8:57PM CDT
BCRX: 10.03 (-0.04), VSR: 2.96 (-0.03), TKMR: 17.26 (+0.85), NNVC: 3.24 (-0.15), INO: 10.18 (-0.82), SPY: 204.01 (-0.23), CMRX: 33.52 (+1.28), APT: 2.93 (+0.01), HEB: 0.28 (+0.01), SRPT: 15.19 (-0.13), SMED: 4.33 (-0.05), NLNK: 31.00 (+0.46), PLX: 2.13 (+0.04), LAKE: 11.40 (+0.34), NSPH: 0.44 (unch)
Ebola-stoked stocks rise
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 2:49PM CDT
BCRX: 10.03 (-0.04), VSR: 2.96 (-0.03), TKMR: 17.26 (+0.85), NNVC: 3.24 (-0.15), INO: 10.18 (-0.82), CMRX: 33.52 (+1.28), APT: 2.93 (+0.01), HEB: 0.28 (+0.01), SRPT: 15.19 (-0.13), SMED: 4.33 (-0.05), NLNK: 31.00 (+0.46), PLX: 2.13 (+0.04), LAKE: 11.40 (+0.34), NSPH: 0.44 (unch)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 8:21AM CDT
CERS: 4.32 (-0.09), SCOK: 3.01 (-0.28), NCR: 27.75 (-0.50), TKMR: 17.26 (+0.85), VSR: 2.96 (-0.03), CNL: 53.56 (+0.20), PT: 1.72 (+0.03), CMRX: 33.52 (+1.28), QEP: 23.27 (-1.25), IBM: 164.58 (+0.42), APT: 2.93 (+0.01), PLX: 2.13 (+0.04), NLNK: 31.00 (+0.46), IBIO: 1.11 (+0.06), LAKE: 11.40 (+0.34), SHOR: 7.51 (-0.70)
Recent News posted below.
Chimerix Inc CMRX other info.
http://investorshangout.com/Chimerix-Inc-CMRX-90543/
CMRX Chimerix Inc Recent Headline News
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 22.85 (+0.24), JNJ: 108.27 (+0.11), BCRX: 10.04 (-0.03), NAVB: 1.24 (+0.08), CMRX: 33.52 (+1.28), SRPT: 15.20 (-0.12), NBS: 6.90 (+0.73), TKMR: 17.26 (+0.85), GSK: 45.84 (+0.10), CEMP: 13.85 (+0.25), OMER: 19.51 (+0.53)
Chimerix's Brincidofovir Selected for Use in Ebola Clinical Trial in West Africa by International Consortium
GlobeNewswire - Thu Nov 13, 11:30AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that its investigational broad-spectrum antiviral brincidofovir has been selected as one of two investigational agents to be evaluated in a clinical study in patients with confirmed Ebola Virus Disease in west Africa. Chimerix and the University of Oxford are in the process of finalizing a definitive agreement for supplying brincidofovir for the planned clinical trial.
CMRX: 33.52 (+1.28)
Global Ebola Viral Infections Clinical Trials Report H2, 2014 - Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/wtw3b6/ebola_viral) has announced the addition of the "Ebola Viral Infections Global Clinical Trials Review, H2, 2014" report to their offering. Ebola Viral Infections Global Clinical Trials Review, H2, 2014" provides data on the Ebola Viral Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ebola Viral Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ebola Viral Infections. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Tekmira Pharmaceuticals Corp. - Sarepta Therapeutics, Inc. - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Chimerix, Inc. Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Academy of Military Medical Sciences - University of Oxford For more information visit http://www.researchandmarkets.com/research/wt...bola_viral
INO: 10.18 (-0.82), CMRX: 33.52 (+1.28), SRPT: 15.20 (-0.12), TKMR: 17.26 (+0.85), GSK: 45.84 (+0.10)
Chimerix to Present at the Stifel Healthcare Conference
GlobeNewswire - Tue Nov 11, 7:01AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 3:35pm EST at The New York Palace Hotel in New York.
CMRX: 33.52 (+1.28)
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 35.70 (+0.48), CMRX: 33.52 (+1.28), CVM: 0.63 (-0.02), ADMP: 4.01 (-0.08), GNCA: 8.99 (+0.09)
InsiderInsights.com Daily Round Up 11/6/14: Chimerix, Biolase, Barrett Business Services, Ares Capital
InsiderInsights - at Seeking Alpha - Fri Nov 07, 1:06PM CST
72.01 (+0.44), CBG: 32.39 (-0.01), PBFX: 24.20 (+0.52), LLY: 67.22 (-0.11), RL: 175.58 (+1.34), GOOG: 535.61 (-8.79), AER: 43.13 (-0.42), DO: 35.41 (-0.40), TPVG: 14.62 (+0.06), ARCC: 16.26 (-0.12), CMRX: 33.52 (+1.28), OPK: 8.24 (-0.05), BIOL: 2.37 (+0.02), WRI: 35.93 (+0.33), BBSI: 22.36 (-0.24), CUDA: 35.21 (-0.13), ACGL: 56.90 (-0.40), KPTI: 40.19 (+0.42) Chimerix's (CMRX) CEO Michelle Berrey on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 12:33PM CST
CMRX: 33.52 (+1.28)
Chimerix misses by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:19AM CST
CMRX: 33.52 (+1.28)
Chimerix Announces Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial results and a corporate update for the third quarter 2014.
CMRX: 33.52 (+1.28)
Chimerix Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock
GlobeNewswire - Wed Nov 05, 3:38PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the completion of an underwritten public offering of 4,197,500 shares of its common stock, including 547,500 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Chimerix at a price to the public of $29 per share. The gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, were approximately $121.7 million. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
CMRX: 33.52 (+1.28), MS: 35.65 (-0.04)
Chimerix Names Two New Executives: Peter Payne as Senior Vice President, Business Development and Corporate Strategy, and Roberto Guzman, JD, MBA, MCLFS, as Vice President, Corporate Compliance
GlobeNewswire - Mon Nov 03, 5:31PM CST
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals, today announced the appointments of Peter Payne as Senior Vice President of Business Development and Corporate Strategy, and Roberto Guzman as Vice President of Corporate Compliance. Mr. Payne will oversee Chimerix's Business Development efforts as the company continues to derive additional value from its pipeline and evaluate complementary products that may further enhance the company's portfolio. Mr. Guzman will have responsibility for the design, implementation, and oversight of the Chimerix Compliance Program.
CMRX: 33.52 (+1.28)
Chimerix to Announce Third Quarter Financial Results on November 7, 2014
GlobeNewswire - Fri Oct 31, 4:58PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it will report financial results for the third quarter ended September 30, 2014, on Friday, November 7, 2014, before the market opens. Chimerix's management team will host a live conference call and audio webcast at 8:30 a.m. ET on Friday, November 7, 2014 to discuss the Company's results and to provide a business overview.
CMRX: 33.52 (+1.28)
Chimerix Prices Public Offering of Common Stock
GlobeNewswire - Thu Oct 30, 5:37PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the pricing of an underwritten public offering of 3,650,000 shares of its common stock at a price to the public of $29 per share. The gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, are expected to be approximately $105.9 million. The offering is expected to close on or about November 5, 2014, subject to customary closing conditions. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
CMRX: 33.52 (+1.28), MS: 35.65 (-0.04)
Chimerix Announces Commencement of Public Offering of Common Stock
GlobeNewswire - Wed Oct 29, 4:30PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it intends to offer and sell, subject to market and other conditions, approximately $105,000,000 of its common stock in an underwritten public offering. In connection with this offering, Chimerix expects to grant the underwriters a 30-day option to purchase up to approximately $15,750,000 of additional shares of its common stock. Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering, and Cowen and Company, LLC, Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as co-lead managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
CMRX: 33.52 (+1.28), JPM: 60.34 (+0.06), MS: 35.65 (-0.04)
CDC issues new guidelines over Ebola
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:10AM CDT
BCRX: 10.04 (-0.03), VSR: 2.96 (-0.03), TKMR: 17.26 (+0.85), NNVC: 3.24 (-0.15), INO: 10.18 (-0.82), CMRX: 33.52 (+1.28), APT: 2.93 (+0.01), HEB: 0.28 (+0.01), SRPT: 15.20 (-0.12), SMED: 4.33 (-0.05), NLNK: 31.00 (+0.46), PLX: 2.13 (+0.04), LAKE: 11.40 (+0.34), NSPH: 0.44 (unch)
Ebola Hits NYC: Time To Panic
Matthew Finston - at Seeking Alpha - Mon Oct 27, 7:45AM CDT
BCRX: 10.03 (-0.04), TKMR: 17.26 (+0.85), NNVC: 3.24 (-0.15), INO: 10.18 (-0.82), CMRX: 33.52 (+1.28), APT: 2.93 (+0.01), HEB: 0.28 (+0.01), SRPT: 15.19 (-0.13), NLNK: 31.00 (+0.46), PLX: 2.13 (+0.04), SMED: 4.33 (-0.05), LAKE: 11.40 (+0.34), NSPH: 0.44 (unch), OSUR: 8.80 (+0.03)
Mali confirms first Ebola case
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 3:48AM CDT
BCRX: 10.03 (-0.04), GOLD: 67.74 (-1.01), AU: 9.26 (-0.30), VSR: 2.96 (-0.03), TKMR: 17.26 (+0.85), NNVC: 3.24 (-0.15), INO: 10.18 (-0.82), CMRX: 33.52 (+1.28), APT: 2.93 (+0.01), HEB: 0.28 (+0.01), SRPT: 15.19 (-0.13), SMED: 4.33 (-0.05), NLNK: 31.00 (+0.46), PLX: 2.13 (+0.04), LAKE: 11.40 (+0.34), NSPH: 0.44 (unch)
NYC doctor tests positive for Ebola; futures slip
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 8:57PM CDT
BCRX: 10.03 (-0.04), VSR: 2.96 (-0.03), TKMR: 17.26 (+0.85), NNVC: 3.24 (-0.15), INO: 10.18 (-0.82), SPY: 204.01 (-0.23), CMRX: 33.52 (+1.28), APT: 2.93 (+0.01), HEB: 0.28 (+0.01), SRPT: 15.19 (-0.13), SMED: 4.33 (-0.05), NLNK: 31.00 (+0.46), PLX: 2.13 (+0.04), LAKE: 11.40 (+0.34), NSPH: 0.44 (unch)
Ebola-stoked stocks rise
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 2:49PM CDT
BCRX: 10.03 (-0.04), VSR: 2.96 (-0.03), TKMR: 17.26 (+0.85), NNVC: 3.24 (-0.15), INO: 10.18 (-0.82), CMRX: 33.52 (+1.28), APT: 2.93 (+0.01), HEB: 0.28 (+0.01), SRPT: 15.19 (-0.13), SMED: 4.33 (-0.05), NLNK: 31.00 (+0.46), PLX: 2.13 (+0.04), LAKE: 11.40 (+0.34), NSPH: 0.44 (unch)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 8:21AM CDT
CERS: 4.32 (-0.09), SCOK: 3.01 (-0.28), NCR: 27.75 (-0.50), TKMR: 17.26 (+0.85), VSR: 2.96 (-0.03), CNL: 53.56 (+0.20), PT: 1.72 (+0.03), CMRX: 33.52 (+1.28), QEP: 23.27 (-1.25), IBM: 164.58 (+0.42), APT: 2.93 (+0.01), PLX: 2.13 (+0.04), NLNK: 31.00 (+0.46), IBIO: 1.11 (+0.06), LAKE: 11.40 (+0.34), SHOR: 7.51 (-0.70)
